Thomas Johnston has been promoted to CEO of Mucosis to take over from Govert Schouten, who is leaving the Dutch clinical-stage biotech to found an internet start-up.
Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.
Prior to that he served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with companies such as Comcast, Microsoft, and Schlumberger.
John Lambert, chairman of the Mucosis board of directors, said: “Tom has more than 15 years of leadership experience in the biotech and other industries and has been an invaluable member of our executive management team.
“Given Tom’s substantial commercial experience and familiarity with the Company, we are confident he is the right person to lead Mucosis as we execute our strategy and further advance the development and commercialisation of the Mimopath platform including our RSV vaccine candidate.”
During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial virus (RSV) candidate SynGEM into pre-clinical studies.